Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 12, Number 8—August 2006

Antibody Response to Pneumocystis jirovecii

Kieran R. Daly*†, Laurence Huang‡, Alison Morris§, Judy Koch*†, Kristina Crothers‡¶, Linda Levin†, Shary Eiser‡, Supriya Satwah†, Patrizia Zucchi‡#, and Peter D. Walzer*†Comments to Author 
Author affiliations: *Veterans Affairs Medical Center, Cincinnati, Ohio, USA; †University of Cincinnati, Cincinnati, Ohio, USA; ‡University of California, San Francisco, California, USA; §University of Southern California, Los Angeles, California, USA; ¶Yale University School of Medicine, New Haven, Connecticut, USA; #University of Pavia, Pavia, Italy

Main Article

Table 4

Antibody levels to major surface glycoprotein A in Pneumocystis pneumonia (PCP) patients by history of PCP and week of observation*

Week Combined
No history of PCP
History of PCP
n Geometric mean (95% CI) n Geometric mean (95% CI) n Geometric mean (95% CI)
Baseline (0) 78 5.6 (3.9–7.9) 59 5.8 (3.9–8.7) 19 4.7 (2.1–10.5)
1–2 24 12.0 (6.7–21.4) 18 13.7 (7.0–26.8) 6 7.6 (1.2–47.4)
3–4 17 11.5 (5.2–25.3) 11 13.7 (4.3–43.5) 6 7.3 (1.1–48.9)
5–6 17 5.1 (2.3–11.3) 13 4.0 (1.9–8.2) 4 5.7 (0.2–207.9)

*n = no. patients who were observed at the specified follow-up time and at baseline. CI, confidence interval.

Main Article

Page created: December 09, 2011
Page updated: December 09, 2011
Page reviewed: December 09, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.